期刊
EMBO JOURNAL
卷 37, 期 19, 页码 -出版社
WILEY
DOI: 10.15252/embj.201694813
关键词
adenosine deaminases acting on RNA (ADAR); cardiovascular disease; Filamin A (FLNA); hypertension; RNA editing
资金
- Austrian Science Foundation [F4313, P22956, P27166-B23, W1207]
- Mahlke-Obermann Stiftung
- European Union [609431]
- EC [QLG1-CT-2001-00869, LSHC-CT-2006-037731]
- Austrian Federal Government's GEN-AU program Austromouse [GZ 200.147/1-VI/1a/2006]
- Austrian Science Fund [FWF-P18421, FWF-P18782, SFB-23-B13, DK W1212]
- European Research Council [311257]
- Israel Science Foundation [1380/14]
- German Federal Ministry of Education and Research [01KX1012]
- Austrian Science Fund (FWF) [P27166, P26882, P22956, W1207] Funding Source: Austrian Science Fund (FWF)
Epitranscriptomic events such as adenosine-to-inosine (A-to-I) RNA editing by ADAR can recode mRNAs to translate novel proteins. Editing of the mRNA that encodes actin crosslinking protein Filamin A (FLNA) mediates a Q-to-R transition in the interactive C-terminal region. While FLNA editing is conserved among vertebrates, its physiological function remains unclear. Here, we show that cardiovascular tissues in humans and mice show massive editing and that FLNA RNA is the most prominent substrate. Patient-derived RNA-Seq data demonstrate a significant drop in FLNA editing associated with cardiovascular diseases. Using mice with only impaired FLNA editing, we observed increased vascular contraction and diastolic hypertension accompanied by increased myosin light chain phosphorylation, arterial remodeling, and left ventricular wall thickening, which eventually causes cardiac remodeling and reduced systolic output. These results demonstrate a causal relationship between RNA editing and the development of cardiovascular disease indicating that a single epitranscriptomic RNA modification can maintain cardiovascular health.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据